PR.com: Business Directory, Press Releases, Jobs, Products, Services, Articles
 
Businesses Articles Press Releases Follow @PRcom
Press Release Pricing | News by Category | News by Country | News by US Region | Recent News | PR.com News on Your Site
 

Press Releases

 
iHealthcareAnalyst, Inc.

Press Release


Receive press releases from iHealthcareAnalyst, Inc.: By Email RSS Feeds:

Global Heparin Anticoagulant Market by Unfractionated, Low Molecular Weight, Ultra-Low Molecular Weight Heparin, and Forecast, New Report by iHealthcareAnalyst, Inc.


Heparin Anticoagulant Market by Products (Unfractionated Heparin, Low Molecular Weight Heparin, Ultra-Low Molecular Weight Heparin) 2016-2020

Maryland Heights, MO, March 02, 2017 --(PR.com)-- The global heparin anticoagulant market is estimated to reach USD 10.8 Billion in 2020, growing at a CAGR of 4.4% from 2016 to 2020, due to its rising demand in clinical applications worldwide.

Browse Heparin Anticoagulant Market by Products (Unfractionated Heparin, Low Molecular Weight Heparin, Ultra-Low Molecular Weight Heparin) 2016-2020 at https://www.ihealthcareanalyst.com/report/heparin-anticoagulant-market/

Heparin is an anticoagulant (blood thinner) that prevents the formation of blood clots. Heparin is used to treat and prevent blood clots in the veins, arteries, or lung. It is also used before surgery to reduce the risk of blood clots. It is used to treat and prevent deep vein thrombosis and pulmonary embolism (collectively known as venous thromboembolism) and is also used as part of the treatment of myocardial infarction and unstable angina. Heparin is used on the inside surfaces of various devices such as test tubes and kidney dialysis machines. Heparin is the foremost clinical anticoagulant with more than 500 million doses consumed globally each year. Heparin and related molecules exhibit a large number of newly discovered biological activities with optimum therapeutic potential. Advantages of heparin such as immediate onset of action, short half-life, simple laboratory monitoring, ability to be reversed (protamine), and low cost have led to its use worldwide. The major clinical applications of heparin include prevention of blood clotting during dialysis, unwanted blood clotting during open-heart surgery, and treatment of deep vein thrombosis and pulmonary embolism.

The global heparin anticoagulant market segmentation is based on products (unfractionated heparin, low molecular weight heparin, ultra-low molecular weight heparin).

The global heparin anticoagulant market report provides market size (Revenue USD Million 2013 to 2020), market share, market trends and forecasts growth trends (CAGR%, 2016 to 2020). The global heparin anticoagulant market research report is further segmented by geography into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World. The global heparin anticoagulant market report also provides the detailed market landscape, market drivers, restraints, opportunities), market attractiveness analysis and profiles of major competitors in the global market including company overview, financial snapshot, key products, technologies and services offered, and recent developments.

Major players operating in the global heparin anticoagulant market and included in this report are Dr. Reddy's Laboratories Ltd., LEO Pharma A/S, Mylan N.V., Pfizer, Inc., Sanofi S.A., Syntex S.A., and Teva Pharmaceutical Industries Ltd.

To request Table of Contents and Sample Pages of this report visit:
https://www.ihealthcareanalyst.com/report/heparin-anticoagulant-market/

About Us
iHealthcareAnalyst, Inc. is a global healthcare market research and consulting company providing market analysis, and competitive intelligence services to global clients. The company publishes syndicate, custom and consulting grade healthcare reports covering animal healthcare, biotechnology, clinical diagnostics, healthcare informatics, healthcare services, medical devices, medical equipment, and pharmaceuticals.

In addition to multi-client studies, we offer creative consulting services and conduct proprietary single-client assignments targeted at client’s specific business objectives, information needs, time frame and budget. Please contact us to receive a proposal for a proprietary single-client study.

Contact Us
iHealthcareAnalyst, Inc.
2109, Mckelvey Hill Drive,
Maryland Heights, MO 63043
United States
Email: sales@ihealthcareanalyst.com
Website: https://www.ihealthcareanalyst.com
Contact Information
iHealthcareAnalyst, Inc.
Ana Aitawa
(314) 500-7508
Contact
https://www.ihealthcareanalyst.com/

Click here to view the list of recent Press Releases from iHealthcareAnalyst, Inc.
Promote Your Business